Articles On Acrux (ASX:ACR)

Acrux Ltd (ASX:ACR) has been approved to begin U.S. commercialisation activities for its Nitroglycerin Ointment 0.4% targeting pain related to chronic anal fissures, with this marking the fourth Acrux product approved by the FDA. The oin...

ASX drops as tech stocks continue to slide Gold rebounds ahead of US inflation data South32 falls as Mozambique unrest disrupts production   The ASX extended its losses on Wednesday following the weak sentiment from Wall Street overnight....

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

  Michael Kotsanis – CEO & Managing Director – Acrux Limited (ASX:ACR) is a speciality pharma company with a successful track record of commercialising topically applied pharmaceuticals.

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

ASX 200 down on Tuesday; energy and iron ore stocks rise BHP’s profit up 2pc, but dividend cut. Lovisa drops 12pc; Zip Co loses over 10pc despite strong revenue   The ASX traded cautiously following a mixed session on Wall Street. At the...

Acrux’s stock jumped after the US FDA approved its acne gel This new product addresses a market worth $37 million annually Island Pharma has begun patient screening for Phase 2 study on dengue fever   Acrux shares surge after US FDA appro...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Momentum investing involves taking advantage of, and making profits from, upward trends in a stock. The strategy takes the position that the stock market’s recent winners will remain winners. Note that there is a big difference between mome...

This week’s Bulls N’ Bears ASX Runner of the Week is… Regeneus Ltd. Its share price surged 220 per cent to join fellow movers and shakers Acrux Ltd and Perpetual Resources.

Specialty pharmaceutical company Acrux (ASX: ACR) and its partner TruPharma have launched a generic version of Aczone 5% Gel on the US market to treat acne vulgaris. Known as Dapsone 5% Gel, the prescription topical medicine was created to...

Acrux Ltd (ASX: ACR) shares are avoiding the market weakness and rocketing higher on Wednesday. In morning trade, the ASX healthcare stock was up as much as 110% to 9.9 cents. To put that into context, a $10,000 investment yesterday aftern...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Momentum trading involves taking advantage of, and making profits from, upward trends in a stock. It involves betting that the stock market’s recent winners will remain winners. One of the best known momentum traders in the world is hedge f...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today.   ICYMI Leade...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Ask any chief of a development-stage biotech about the prospect of a partnering or licencing deal and they will refer to a multitude of discussion with big pharma – all couched in suitably vague terms. But when Dimerix (ASX:DXB) chief Dr Ni...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Tim Boreham outlines the rise and fall of IDT Australia, and its potential revival in the cannabis and psychedelic drug market. by Tim Boreham ASX Code: ((IDT)) Share price: 6.7 cents Shares on issue: 351,337,149 Market cap: $23.5m Chief ex...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

The ASX was higher by around 2.5% in July The best sectors were Tech and Energy We look at the best and worst performing ASX stocks for the month For the month of July, most major indexes on the ASX rose by around 2.5%. Name % Change...

S&P/ASX 200 closes in the red today: -0.35%, as US stock markets enjoy a July 4 chilli dog, or something Sectors-wise, Telcos are ringing in the gainz… annnd that’s about it. Okay, Utilities are going alright  Standout stocks: Krakatoa...

Acrux (ACR) receives approval from the US FDA to review a generic version of its nitroglycerin ointment at 0.4 per cent concentration The company applied for an abbreviated new drug application for the generic version, if approved by the...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

By Tim Boreham ASX code: ((DXB)) Share price: 7.0c Shares on issue: 320,748,666* Market cap: $22.5m Chief executive officer: Dr Nina Webster Board: Hugh Alsop (chair), Dr Webster, Dr Sonia Poli, Clinton Snow Financials (March quarter 2023):...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week   Earlier this week, Pfizer surprised the market by say...

The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit   Medicare, telehealth and mental...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Acrux (ACR) reaches agreement for EUR 4.10 million (A$6.41 million) buyout of future Lenzetto royalties Lenzetto is used to treat oestrogen deficiency symptoms in postmenopausal women Acrux CEO and MD Michael Kotsanis said the deal im...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Acrux (ACR) and its partner, Padagis, launch a prilocaine and lidocaine cream product in the United StatesThe cream is used as a topical anaesthetic on the skin for numbing or as a pre-treatment for infiltration anaesthesiaThe company says...

Highlights The ASX 200 benchmark index closed in the green today (21 December), gaining 90.80 points or 1.29% to end at 7,115.10 points. Over the last five days, the index has lost 1.88% and 3.26% over the last 52 weeks. Utilities was...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...